OTR-8100 / Shanghai Blueray Biopharma, OTR Therapeutics - LARVOL DELTA

OTR-8100, a potent and selective EED inhibitor, demonstrates synergistic antitumor activity with targeted therapies in solid tumors (EORTC-NCI-AACR 2026) - "Abstract will be available as of 4 November (with consent of the author)"

Oncology • Solid Tumor

Phase I/IIa Study of BR1733 in Subjects With Advanced Cancers (clinicaltrials.gov) - P1/2 | N=191 | Active, not recruiting | Sponsor: Shanghai Blueray Biopharma Co., Ltd. | Not yet recruiting ➔ Active, not recruiting

Enrollment closed • Metastases • Monotherapy • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma

Discovery of BR1733 for the treatment of SWI/SNF deficient or highly vascularized solid tumor (AACR 2023) - "BR1733 also inhibited tumor angiogenesis and showed tumor growth inhibition in several CDX models of highly vascularized solid tumors such as HCC and RCC. BR1733 is currently in Phase I clinical trials."

Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Renal Cell Carcinoma • Solid Tumor • CDKN2A • EZH2 • TET1

Phase I/IIa Study of BR1733 in Subjects With Advanced Cancers (clinicaltrials.gov) - P1/2 | N=191 | Not yet recruiting | Sponsor: Shanghai Blueray Biopharma Co., Ltd.

Metastases • Monotherapy • New P1/2 trial • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • Solid Tumor • T Cell Non-Hodgkin Lymphoma